Close Menu

    Subscribe to Updates

    Get the latest information from JBUON.

    What's Hot

    Two Cases of Pancreatic Metastases from Renal Cell Carcinoma and Review of the Literature

    April 17, 2025

    Exploration of Matrix Metalloproteinase-9 and Interleukin-8 in Breast Cancer Patients with No Lymph Node Involvement

    March 14, 2025

    Surgical Treatment of Right Atrial Metastasis of the Malignant Melanoma: A Case Report

    March 6, 2025
    Facebook X (Twitter) Instagram
    JBUONJBUON
    • How to Submit
    • Author Guidelines
    Facebook X (Twitter) Instagram
    SUBMIT
    • Home
    • Browse Issues
      • In Press
      • Current Issue
      • Archives
    • About Journal
      • Journal Information
      • Editorial Board
      • Bibliographic Listings
      • Editorial Policy
      • Ethics and Malpractice Statement
    • For Authors
      • How To Submit
      • Submit Article
      • Downloads
    • Contact
    JBUONJBUON
    Home»Issues»Volume 26, Issue 6»The prognostic impact of ABO blood groups and Rhesus factor in patients with upper tract urothelial carcinoma
    Volume 26, Issue 6

    The prognostic impact of ABO blood groups and Rhesus factor in patients with upper tract urothelial carcinoma

    November 30, 2021Updated:April 29, 20242 Mins Read
    Share
    Facebook Twitter Email

    Djordje Radisavcevic1, Zoran Dzamic1,2, Emre Cico1, Sandra Sipetic Grujicic3, Bogomir Milojevic1,2

    1Faculty of Medicine, University of Belgrade, Belgrade, Serbia.

    2Clinic of Urology, Clinical Center of Serbia, Belgrade, Serbia.

    3Institute of Epidemiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.

    Summary

    Purpose: To evaluate the prognostic impact of ABO blood groups and Rhesus factor in patients with upper tract urothelial cancer (UTUC).

    Methods: The study included 78 consecutive patients who were treated with RNU. Demographic and clinicopathologic factors were analyzed using x2 or an unpaired t-test. Recurrence-free probabilities and cancer-specific survival (CSS) were estimated by the Kaplan-Meier method, and the log-rank test was used for the statistical differences. Univariate and multivariate Cox proportional hazard regression models were used to evaluate the association between various clinicopathologic factors with disease recurrence and CSS.

    Results: ABO blood groups antigen and Rhesus factor were not significantly associated with any clinicopathologic and patient characteristics. At a median follow up of 25.2 months, 42.3% of the patients experienced disease recurrence and 15.4% died of UTUC. History of bladder tumor (HR 1.34; 95% CI, 0.76-2.34; p=0.3) was associated with disease recurrence. ABO blood group (p=0.3) and Rhesus factor (HR 6.7; 95% CI, 0.76-59.2; p=0.08) were not independently associated with disease recurrence. There was no difference in CSS when we compared ABO blood groups and Rhesus factor. ABO blood group and Rhesus factor were not significantly associated with worse disease recurrence-free survival (p=0.4, log rank), (p=0.8, log rank) respectively. In addition, ABO blood group was not significantly associated with CSS (p=0.55), as well as Rhesus factor (p=0.3).

    Conclusions: ABO blood group antigens and Rhesus factor expression were unable to predict outcomes in a single-center series of consecutive patients who were treated with radical nephroureterectomy (RNU).

    Key words: ABO blood group, radical nephroureterectomy, recurrence, Rhesus factor, upper tract urothelial carcinoma.

    Full Text: PDF

    Original Article
    Previous ArticleRadioactive iodine treatment planning for differentiated thyroid carcinoma: Comparison of different machine learning classification models
    Next Article Different influences of risk factors on the development of head and neck tumors and other oncological diagnoses

    Related Articles

    Exploration of Matrix Metalloproteinase-9 and Interleukin-8 in Breast Cancer Patients with No Lymph Node Involvement

    Volume 27, 2024

    Malignant Diseases as a Reason for Interventions by Emergency Medical Teams in Barajevo 2023

    Volume 27, 2024

    MicroRNA signatures landscape in renal cell carcinoma – related epithelial to mesenchymal transition

    Volume 26, Issue 6
    Don't Miss
    Volume 27, 2024

    Two Cases of Pancreatic Metastases from Renal Cell Carcinoma and Review of the Literature

    April 17, 2025

    Dimosthenis Chrysikos1, Spiros Delis2, Charina Triantopoulou2, Evgenia Charitaki2, Nikos Kokoroskos2, Nikolaos Taprantzis1*, Amir Shihada1, Konstantinos…

    Exploration of Matrix Metalloproteinase-9 and Interleukin-8 in Breast Cancer Patients with No Lymph Node Involvement

    March 14, 2025

    Surgical Treatment of Right Atrial Metastasis of the Malignant Melanoma: A Case Report

    March 6, 2025

    Abdominal Aortic Aneurysm and Radiation Therapy

    October 28, 2024
    Our Picks

    MicroRNA signatures landscape in renal cell carcinoma – related epithelial to mesenchymal transition

    December 1, 2021

    Chromosomal instability landscape in uveal melanoma

    December 1, 2021

    Biomarkers and common oral cancers: Clinical trial studies

    December 1, 2021

    Subscribe to Updates

    About Us
    About Us

    Journal of BUON (Print ISSN: 1107-0625, Electronic ISSN: 2241-6293) is an independent Open Access Journal, published by BAKIS Productions LTD, and appears exclusively on the internet. It is covered/indexed in Current Awareness in Biological Sciences (BIO-BASE), EMBASE/Excerpta Medica.
    We're accepting new manuscripts right now.

    Email Us: editorial_office@jbuon.com
    Contact: Available soon

    Editorial Picks

    MicroRNA signatures landscape in renal cell carcinoma – related epithelial to mesenchymal transition

    December 1, 2021

    Chromosomal instability landscape in uveal melanoma

    December 1, 2021

    Biomarkers and common oral cancers: Clinical trial studies

    December 1, 2021
    Get in Touch

    Editor-in-Chief
    Athanasios E. Athanasiou,
    Department of Medical Oncology,
    Metaxa Cancer Hospital, Botassi 51, 18537, Piraeus, Greece
    Editorial Office: editorial_office@jbuon.com

    Publishing support
    EManuscript Technologies
    # 9, First Floor, Vinnse Towers
    Wheeler Road Extension, St. Thomas Town, Bangalore 560 084, INDIA
    E: journals@emanuscript.in 
    W : www.emanuscript.in

     

    • Home
    • Author Guidelines
    • Site Map
    • Contact Us
    © 2025 JBUON Powered by EManuscript.

    Type above and press Enter to search. Press Esc to cancel.